- Home
- IONS
as of 02-13-2026 3:46pm EST
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 13.5B | IPO Year: | 1991 |
| Target Price: | $84.09 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 22 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.95 - $86.74 | Next Earning Date: | 02-25-2026 |
| Revenue: | $966,957,000 | Revenue Growth: | 20.41% |
| Revenue Growth (this year): | 29.79% | Revenue Growth (next year): | 0.46% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -302662000.0 | FCF Growth: | N/A |
AI-Powered IONS Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Ionis Pharmaceuticals Inc. (IONS)
EVP Research
Avg Cost/Share
$81.81
Shares
15,642
Total Value
$1,278,913.96
Owned After
38,312
Director
Avg Cost/Share
$82.72
Shares
5,000
Total Value
$413,588.50
Owned After
56,344
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$85.79
Shares
29,430
Total Value
$2,524,820.30
Owned After
254,497
SEC Form 4
EVP, Chief Scientific Officer
Avg Cost/Share
$82.89
Shares
85,089
Total Value
$7,056,215.53
Owned After
80,293
EVP, Chief Business Officer
Avg Cost/Share
$82.96
Shares
5,296
Total Value
$439,364.10
Owned After
45,413
SEC Form 4
EVP Research
Avg Cost/Share
$82.93
Shares
6,179
Total Value
$512,446.10
Owned After
38,312
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$82.72
Shares
62,970
Total Value
$5,208,979.15
Owned After
254,497
SEC Form 4
EVP, Chf Clinical Develop Ofcr
Avg Cost/Share
$83.45
Shares
6,179
Total Value
$515,629.52
Owned After
69,702
SEC Form 4
EVP, Chief Scientific Officer
Avg Cost/Share
$82.95
Shares
5,885
Total Value
$488,140.74
Owned After
80,293
SEC Form 4
EVP, Corp and Development Ops
Avg Cost/Share
$83.03
Shares
6,179
Total Value
$513,047.93
Owned After
66,247
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Swayze Eric | IONS | EVP Research | Feb 13, 2026 | Sell | $81.81 | 15,642 | $1,278,913.96 | 38,312 | |
| PARSHALL B LYNNE | IONS | Director | Feb 11, 2026 | Sell | $82.72 | 5,000 | $413,588.50 | 56,344 | |
| Monia Brett P | IONS | Chief Executive Officer | Feb 6, 2026 | Sell | $85.79 | 29,430 | $2,524,820.30 | 254,497 | |
| BENNETT C FRANK | IONS | EVP, Chief Scientific Officer | Feb 2, 2026 | Sell | $82.89 | 85,089 | $7,056,215.53 | 80,293 | |
| Baroldi Joseph | IONS | EVP, Chief Business Officer | Jan 30, 2026 | Sell | $82.96 | 5,296 | $439,364.10 | 45,413 | |
| Swayze Eric | IONS | EVP Research | Jan 30, 2026 | Sell | $82.93 | 6,179 | $512,446.10 | 38,312 | |
| Monia Brett P | IONS | Chief Executive Officer | Jan 30, 2026 | Sell | $82.72 | 62,970 | $5,208,979.15 | 254,497 | |
| Schneider Eugene | IONS | EVP, Chf Clinical Develop Ofcr | Jan 30, 2026 | Sell | $83.45 | 6,179 | $515,629.52 | 69,702 | |
| BENNETT C FRANK | IONS | EVP, Chief Scientific Officer | Jan 30, 2026 | Sell | $82.95 | 5,885 | $488,140.74 | 80,293 | |
| Birchler Brian | IONS | EVP, Corp and Development Ops | Jan 30, 2026 | Sell | $83.03 | 6,179 | $513,047.93 | 66,247 |
Compare IONS vs Leading Stocks
See how IONS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IONS Ionis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.